X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2019 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare, Analyse Aventis Pharma with ADCOCK INGRAM HOLDINGS LTD. - S. Africa - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

SANOFI INDIA vs ADCOCK INGRAM (S. Africa) - Comparison Results

SANOFI INDIA    Change

Sanofi India (the erstwhile Aventis Pharma), the 60% subsidiary of Sanofi-Aventis SA, France, is one of the largest pharma MNCs in India with a turnover of over Rs 13.2 bn in CY11. Domestic sales constituted 81% of total sales in CY11 and exports con... More

ADCOCK INGRAM (S. Africa)
   Change

Adcock Ingram is a leading South African pharmaceutical manufacturer, marketer and distributor. The company occupies 10% share of the private pharmaceutical market in South Africa with a strong presence in over-the-counter (OTC) brands. Adcock is als... More

DO YOU LIKE THESE REPORTS? TELL US!

Financials

 SANOFI INDIA   ADCOCK INGRAM
EQUITY SHARE DATA
    SANOFI INDIA
Dec-17
ADCOCK INGRAM
Jun-14
SANOFI INDIA/
ADCOCK INGRAM
5-Yr Chart
Click to enlarge
High Rs4,945368-   
Low Rs3,901266-   
Sales per share (Unadj.) Rs1,081.8109.6-  
Earnings per share (Unadj.) Rs141.6-27.6-  
Cash flow per share (Unadj.) Rs185.9-22.9-  
Dividends per share (Unadj.) Rs33.000-  
Dividend yield (eoy) %0.70-  
Book value per share (Unadj.) Rs868.886.0-  
Shares outstanding (eoy) m23.03168.78-   
Bonus/Rights/Conversions ---  
Price / Sales ratio x4.12.9 141.3%   
Avg P/E ratio x31.2-11.5 -272.1%  
P/CF ratio (eoy) x23.8-13.9 -171.7%  
Price / Book Value ratio x5.13.7 138.1%  
Dividend payout %23.30-   
Avg Mkt Cap Rs m101,86253,502 190.4%   
No. of employees `0003.24.3 75.4%   
Total wages/salary Rs m3,6853,358 109.7%   
Avg. sales/employee Rs Th7,691.94,307.3 178.6%   
Avg. wages/employee Rs Th1,137.7782.2 145.5%   
Avg. net profit/employee Rs Th1,006.5-1,085.3 -92.7%   
INCOME DATA
Net Sales Rs m24,91418,491 134.7%  
Other income Rs m807129 623.2%   
Total revenues Rs m25,72118,621 138.1%   
Gross profit Rs m5,372-3,204 -167.6%  
Depreciation Rs m1,022798 128.1%   
Interest Rs m11501 2.2%   
Profit before tax Rs m5,146-4,374 -117.7%   
Minority Interest Rs m0-12 0.0%   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m00-   
Tax Rs m1,886273 690.1%   
Profit after tax Rs m3,260-4,659 -70.0%  
Gross profit margin %21.6-17.3 -124.4%  
Effective tax rate %36.6-6.2 -586.5%   
Net profit margin %13.1-25.2 -51.9%  
BALANCE SHEET DATA
Current assets Rs m14,43213,543 106.6%   
Current liabilities Rs m6,0107,620 78.9%   
Net working cap to sales %33.832.0 105.5%  
Current ratio x2.41.8 135.1%  
Inventory Days Days61111 54.9%  
Debtors Days Days28124 23.0%  
Net fixed assets Rs m7,9917,894 101.2%   
Share capital Rs m23086 268.3%   
"Free" reserves Rs m19,7780-   
Net worth Rs m20,00814,514 137.9%   
Long term debt Rs m05,100 0.0%   
Total assets Rs m27,77027,417 101.3%  
Interest coverage x468.8-7.7 -6,063.2%   
Debt to equity ratio x00.4 0.0%  
Sales to assets ratio x0.90.7 133.0%   
Return on assets %11.8-15.2 -77.7%  
Return on equity %16.3-32.1 -50.8%  
Return on capital %25.8-19.8 -130.1%  
Exports to sales %00-   
Imports to sales %00-   
Net fx Rs m1,0490-   
CASH FLOW
From Operations Rs m4,3511,578 275.7%  
From Investments Rs m-787-485 162.4%  
From Financial Activity Rs m-1,8844,629 -40.7%  
Net Cashflow Rs m1,6805,723 29.4%  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster
The reporting currency for ADCOCK INGRAM (S. Africa) is South Africa Rand. All data has been converted at 5.08 Rs / ZAR

Compare SANOFI INDIA With: MYLAN (US)  ACTAVIS (US)  TEVA PHARMA (Israel)  

Compare SANOFI INDIA With: DR. REDDYS LAB  PIRAMAL ENTERPRISES  FULFORD INDIA  PANACEA BIOTECH  TORRENT PHARMA  



Today's Market

Recapitalisation Package for PSBs: The Pros & Cons(Podcast)

Corporate governance issues with certain companies, uncertainty surrounding national elections and global issues like trade wars, Brexit, have taken a toll on the Indian markets.

Related Views On News

SANOFI INDIA Announces Quarterly Results (2QFY19); Net Profit Up 2.5% (Quarterly Result Update)

Nov 6, 2018 | Updated on Nov 6, 2018

For the quarter ended September 2018, SANOFI INDIA has posted a net profit of Rs 1 bn (up 2.5% YoY). Sales on the other hand came in at Rs 7 bn (up 11.4% YoY). Read on for a complete analysis of SANOFI INDIA's quarterly results.

SANOFI INDIA Announces Quarterly Results (1QFY19); Net Profit Up 35.1% (Quarterly Result Update)

Jul 27, 2018 | Updated on Jul 27, 2018

For the quarter ended June 2018, SANOFI INDIA has posted a net profit of Rs 996 m (up 35.1% YoY). Sales on the other hand came in at Rs 7 bn (up 13.8% YoY). Read on for a complete analysis of SANOFI INDIA's quarterly results.

Aster DM Healthcare (IPO)

Feb 10, 2018

Should you subscribe to the IPO of Aster DM Healthcare Ltd?

Shalby Ltd. (IPO)

Dec 2, 2017

Should you subscribe to the IPO of Shalby Ltd?

The Power of 5 Minutes (The 5 Minute Wrapup)

Jun 16, 2017

Here's what you can expect from The 5 Minute Wrapup in the coming months and years.

More Views on News

Most Popular

The One Real Estate Stock to Buy Now(The 5 Minute Wrapup)

Feb 13, 2019

The real estate sector is ready to make a comeback. This is the stock to consider buying.

Don't Be Afraid of the Market; Buy Stocks Like This One(The 5 Minute Wrapup)

Feb 14, 2019

During this tough period in the market, a contrarian approach holds huge potential upside for this Smart Money Secrets stock.

Small Caps Under Seige: Could This Be A Once-in-a-Decade Wealth Creating Opportunity?(Profit Hunter)

Feb 14, 2019

Don't let the dark clouds hovering over small caps scare you into hiding; it will rain gold as sentiments recover. Indeed, there is a blood bath. And if you are a first time investor, the correction is deep enough to scare you out of markets.

The 4-Point Plan to Accelerate India to a 10 Trillion Dollar Economy(The 5 Minute Wrapup)

Feb 12, 2019

Two questions I have been eagerly waiting to ask you ever since Budget 2019 was announced.

The Train to 'Small-Cap-Profits Land' is Back on the Station!(Profit Hunter)

Feb 15, 2019

Why its great news that prices for small caps over the last few days have been falling like there's no tomorrow.

More

Get the Indian Stock Market's
Most Profitable Ideas

How To Beat Sensex Guide 2019
Get our special report, How to Beat Sensex Nearly 3X Now!
We will never sell or rent your email id.
Please read our Terms

SANOFI INDIA SHARE PRICE


Feb 22, 2019 (Close)

TRACK SANOFI INDIA

  • Track your investment in SANOFI INDIA with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

SANOFI INDIA - GLENMARK PHARMA COMPARISON

COMPARE SANOFI INDIA WITH

MARKET STATS